Syntach AB announces partnership with Meditrial CRO to drive clinical development of groundbreaking Cardiac Support System
LUND, Sweden, Feb. 10, 2023 /PRNewswire/ - Syntach AB ("Syntach") is pleased to announce that it has entered into a partnership agreement with Meditrial Europe Ltd ("Meditrial") to support the clinical and regulatory strategies of Syntach's innovative minimally invasive cardiac support system. Over 64 million people suffer from heart failure, one of...
US based COBRA diagnostic prostate cancer trial reaches recruitment target
SYDNEY, Feb. 9, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce its diagnostic 64Cu SAR-bisPSMA trial COBRA (NCT05249127)1 for patients with prostate cancer has reached its recruitment target. COBRA (Copper-64...
Hugel Achieved Record-High Revenue and Operating Profit
Hugel delivered 2022 revenue of KRW281.7bn, operating profit of KRW102.5bn, up 21.5% YoY and 7.2% YoY, respectively Botulinum toxin's sales soared by 28.9% YoY; European sales in full swing Hugel aims to obtain marketing approval and launch products in the U.S. within this year SEOUL, South Korea, Feb. 9, 2023 /PRNewswire/...
First Prescription for COSELA® (trilaciclib) Issued in China
- COSELA®, the world's first and only myeloprotection drug, was prescribed in Jilin Cancer Hospital on January 28, 2023 - Simcere delivers drug to patients in 908 days from execution of license agreement to first prescription NANJING, China, Feb. 9, 2023 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) ("Simcere"), an innovative global biopharmaceutical company, and G1 Therapeutics,...
AnPac Bio-Medical Science Enters into Definitive Agreement to Acquire Fresh2 Ecommerce Inc, a B2B Asian Food E-commerce Platform
Transaction expected to fuel the Company's growth in the U.S. food market NEW YORK, Feb. 9, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on...
Technoderma Medicines Initiates TDM-180935 Atopic Dermatitis Clinical Program with Phase 1 Dose Escalation Trial
SAN DIEGO, Feb. 9, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing healthy volunteer subjects in its Phase 1 clinical trial of topical TDM-180935 ointment. This first clinical trial in the Atopic Dermatitis (AD) program includes single dose and multidose escalation cohorts in a study...
DNA Data Company, Asa Ren, Raised An Oversubscribed US$8.15M To Build An Indonesia Population DNA Database
JAKARTA, Indonesia, Feb. 9, 2023 /PRNewswire/ -- Asa Ren, a leading DNA data company based in Indonesia, today announced the closing of a new early stage round of fundings of US$ 8.15 Million. This oversubscribed round was co-led by Top Harvest Capital (Silicon Valley USA), Kejora Capital (Kejora-SBI Orbit Fund and Orbit Capital Malaysia), and Marcy Venture Partners (Silicon...
GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea
YONGIN, South Korea, Feb. 9, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that the World Health Organization (WHO) has awarded prequalification to filling and finish plant on February 3 2023, located in Ochang, South Korea. This plant is the largest filling and...
ImmVira Clinical Snapshot: Intratumoral Injected OV (MVR-T3011 IT) Monotherapy Achieved Median PFS of 12.9 Months on Treatment of Melanoma
SHENZHEN, China, Feb. 9, 2023 /PRNewswire/ -- ImmVira's first intratumoral injected OV product MVR-T3011 IT has shown positive efficacy in the course of clinical studies in the U.S. and China as of January 2023, with which the monotherapy treatment significantly prolonged PFS to a median of 12.9 months among melanoma patients who had failed previous immune-oncology treatment. Currently, late-stage...
The National Cancer Society of Malaysia (NCSM), MSD and DoctorOnCall Collaborate In Conjunction with World Cancer Day 2023 to Offer Affordable Health Screenings to Members of the Public
KUALA LUMPUR, Malaysia, Feb. 9, 2023 /PRNewswire/ -- In conjunction with World Cancer Day 2023, The National Cancer Society of Malaysia (Persatuan Kanser Kebangsaan Malaysia) (NCSM), MSD and DoctorOnCall are collaborating to increase public awareness with regard to cancer by offering free basic health screenings and doctor's consultations at the Cancer & Health Screening Clinic at its head office...
